[110]
The point is that Novopharm cannot rely upon the blanket confidentiality of s. 6(8) in a context where the true confidentiality of the s. 6(7) disclosure is being put to the test. If it wants protection for its documents and information under Rule 151 it has to go beyond blanket assertions of confidentiality and speculation and show the Court which documents are truly confidential in accordance with the governing jurisprudence.